Obesity

A retrospective analysis reveals that stopping semaglutide at least 14 days before total joint arthroplasty significantly reduces anesthesia-related complications. This study was presented at the American...

A new study reveals that most patients discontinue GLP-1 receptor agonists within a year, with significantly higher dropout rates among those using them for weight loss rather than diabetes management. ...

The FDA has approved tirzepatide, the first-ever drug option to treat moderate to severe obstructive sleep apnea in adults with obesity.

In a recent randomized, double-blind, placebo-controlled study, researchers found reductions in both body weight and knee pain in individuals with obesity and knee osteoarthritis following weekly treatment...

Researchers investigated semaglutide’s impact on weight-related muscle loss and its potential impact on spinal surgical outcomes, specifically transforaminal lumbar interbody fusion.

Researchers sought to determine whether patients with type 2 diabetes and obesity experience continued type 2 diabetes remission.

On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...

Researchers evaluated the early- and later-stage use of various anti-obesity medications in patients.

Researchers compared the effects of once-weekly semaglutide (2.4 mg) with a placebo during a 52-week period in patients with HFpEF and a BMI of 30 or higher.

Tirzepatide is now approved for a new indication. The dual GIP/GLP-1 agonist was previously approved for treating type 2 diabetes in May 2022.